Background: Opioids may influence the development of Alzheimer’s disease (AD). Some studies have observed AD pathology in the brains of opioid abusers. No study has examined the association between prescription opioid use and dementia-related neuropathologic changes.
Objective: To examine the relationship between prescription opioid or NSAID use and dementia-related neuropathologic changes.
Methods: Within a community-based autopsy cohort (N = 420), we ascertained opioid and nonsteroidal anti-inflammatory drug (NSAID) use over a 10-year period from automated pharmacy data and calculated total standardized daily doses (TSDDs). A neuropathologist assessed outcomes including neuritic plaques, neurofibrillary tangles, and macroscopic infarcts. Outcome measures were dichotomized using established cutpoints. We used modified Poisson regression to calculate adjusted relative risks (RR) and 95% confidence intervals (CI), accounting for participant characteristics and using weighting to account for possible selection bias related to selection into the autopsy sample.
Results: Heavier opioid exposure was not associated with greater neuropathologic changes. For neuritic plaques, the adjusted RR [95% CI] was 0.99 [0.64–1.47] for 91+ TSDDs of opioids versus little to no use, and for neurofibrillary tangles, 0.97 [0.49–1.78]. People with heavy NSAID use had higher risk of neuritic plaques (RR 1.39 [1.01–1.89]) than those with little to no use, as we have previously reported. Neither opioid nor NSAID use was associated with higher risk of macroscopic infarcts or with Lewy body disease.
Conclusion: Prescription opioid use is not associated with dementia-related neuropathologic changes, but heavy NSAID use may be. More research is needed examining chronic pain, its pharmacologic treatments, and neuropathologic changes.
SitesBD, BeachML, DavisMA (2014) Increases in the use of prescription opioid analgesics and the lack of improvement in disability metrics among users. Reg Anesth Pain Med39, 6–12.
2.
ReidMC, BennettDA, ChenWG, EldadahBA, FarrarJT, FerrellB, GallagherRM, HanlonJT, HerrK, HornSD, InturrisiCE, LemtouniS, LinYW, MichaudK, MorrisonRS, NeogiT, PorterLL, SolomonDH, Von KorffM, WeissK, WitterJ, ZacharoffKL (2011) Improving the pharmacologic management of pain in older adults: Identifying the research gaps and methods to address them. Pain Med12, 1336–1357.
3.
AnthonyIC, NorrbyKE, DingwallT, CarnieFW, MillarT, ArangoJC, RobertsonR, BellJE (2010) Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers. Brain133, 3685–3698.
4.
RamageSN, AnthonyIC, CarnieFW, BusuttilA, RobertsonR, BellJE (2005) Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. Neuropathol Appl Neurobiol31, 439–448.
5.
CuiJ, WangY, DongQ, WuS, XiaoX, HuJ, ChaiZ, ZhangY (2011) Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. J Neurosci31, 16227–16240.
6.
SvenssonAL, BuchtN, HallbergM, NybergF (2008) Reversal of opiate-induced apoptosis by human recombinant growth hormone in murine foetus primary hippocampal neuronal cell cultures. Proc Natl Acad Sci U S A105, 7304–7308.
7.
WillnerD, Cohen-YeshurunA, AvidanA, OzerskyV, ShohamiE, LekerRR (2014) Short term morphine exposure in vitro alters proliferation and differentiation of neural progenitor cells and promotes apoptosis via mu receptors. PLoS One9, e103043.
8.
CaoM, LiuF, JiF, LiangJ, LiuL, WuQ, WangT (2013) Effect of c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinase (p38 MAPK) in morphine-induced tau protein hyperphosphorylation. Behav Brain Res237, 249–255.
9.
BlockC, CianfriniL (2013) Neuropsychological and neuroanatomical sequelae of chronic non-malignant pain and opioid analgesia. NeuroRehabilitation33, 343–366.
10.
MoriartyO, McGuireBE, FinnDP (2011) The effect of pain on cognitive function: A review of clinical and preclinical research. Prog Neurobiol93, 385–404.
11.
MayA (2008) Chronic pain may change the structure of the brain. Pain137, 7–15.
12.
ApkarianAV, SosaY, SontyS, LevyRM, HardenRN, ParrishTB, GitelmanDR (2004) Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci24, 10410–10415.
13.
KuchinadA, SchweinhardtP, SeminowiczDA, WoodPB, ChizhBA, BushnellMC (2007) Accelerated brain gray matter loss in fibromyalgia patients: Premature aging of the brain?J Neurosci27, 4004–4007.
14.
DublinS, WalkerRL, GraySL, HubbardRA, AndersonML, YuO, CranePK, LarsonEB (2015) Prescription opioids and risk of dementia or cognitive decline: A prospective cohort study. J Am Geriatr Soc63, 1519–1526.
15.
SonnenJA, LarsonEB, WalkerRL, HaneuseS, CranePK, GraySL, BreitnerJC, MontineTJ (2010) Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology75, 1203–1210.
16.
ArvanitakisZ, GrodsteinF, BieniasJL, SchneiderJA, WilsonRS, KellyJF, EvansDA, BennettDA (2008) Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology70, 2219–2225.
17.
BeeriMS, SchmeidlerJ, LesserGT, MaroukianM, WestR, LeungS, WysockiM, PerlDP, PurohitDP, HaroutunianV (2012) Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol Aging33, 1258–1264.
18.
KukullWA, HigdonR, BowenJD, McCormickWC, TeriL, SchellenbergGD, van BelleG, JolleyL, LarsonEB (2002) Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol59, 1737–1746.
19.
HaneuseS, SchildcroutJ, CraneP, SonnenJ, BreitnerJ, LarsonE (2009) Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology32, 229–239.
20.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
21.
DublinS, WalkerRL, JacksonML, NelsonJC, WeissNS, Von KorffM, JacksonLA (2011) Use of opioids or benzodiazepines and risk of pneumonia in older adults: A population-based case-control study. J Am Geriatr Soc59, 1899–1907.
22.
MirraSS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer’s disease: A commentary. Neurobiol Aging18, S91–S94.
23.
MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology41, 479–486.
24.
BraakE, GriffingK, AraiK, BohlJ, BratzkeH, BraakH (1999) Neuropathology of Alzheimer’s disease: What is new since A. Alzheimer?Eur Arch Psychiatry Clin Neurosci249(Suppl 3), 14–22.
GreenbergSM, VonsattelJP (1997) Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke28, 1418–1422.
27.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBT, National Institute on Aging, Alzheimer’s Association (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
28.
SonnenJA, LarsonEB, CranePK, HaneuseS, LiG, SchellenbergGD, CraftS, LeverenzJB, MontineTJ (2007) Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol62, 406–413.
29.
McKeithIG, DicksonDW, LoweJ, EmreM, O’BrienJT, FeldmanH, CummingsJ, DudaJE, LippaC, PerryEK, AarslandD, AraiH, BallardCG, BoeveB, BurnDJ, CostaD, Del SerT, DuboisB, GalaskoD, GauthierS, GoetzCG, Gomez-TortosaE, HallidayG, HansenLA, HardyJ, IwatsuboT, KalariaRN, KauferD, KennyRA, KorczynA, KosakaK, LeeVM, LeesA, LitvanI, LondosE, LopezOL, MinoshimaS, MizunoY, MolinaJA, Mukaetova-LadinskaEB, PasquierF, PerryRH, SchulzJB, TrojanowskiJQ, YamadaM, Consortium on DLB (2005) Diagnosis and management of dementia with Lewy bodies:Third report of the DLB Consortium. Neurology65, 1863–1872.
30.
WhiteL, PetrovitchH, HardmanJ, NelsonJ, DavisDG, RossGW, MasakiK, LaunerL, MarkesberyWR (2002) Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci977, 9–23.
31.
DublinS, AndersonML, HeckbertSR, HubbardRA, SonnenJA, CranePK, MontineTJ, LarsonEB (2014) Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. J Gerontol A Biol Sci Med Sci69, 609–615.
32.
AndresenEM, MalmgrenJA, CarterWB, PatrickDL (1994) Screening for depression in well older adults: Evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med10, 77–84.
33.
EmiM, WuLL, RobertsonMA, MyersRL, HegeleRA, WilliamsRR, WhiteR, LalouelJM (1988) Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics3, 373–379.
34.
HixsonJE, VernierDT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res31, 545–548.
35.
LarsonEB, WangL, BowenJD, McCormickWC, TeriL, CraneP, KukullW (2006) Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med144, 73–81.
36.
TengE, HasegawaK, HommaA, ImaiY, LarsonE, GravesA, SugimotoK, YamaguchiT, SasakiH, ChiuD, WhiteL (1994) The Cognitive Abilities Screening Instrument (CASI): A practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr6, 45–58; discussion 62.
37.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC.
38.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of theNINCDS-ADRDA Work Group under the auspices of Department of Healthand Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
39.
ZouG (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol159, 702–706.
40.
EfronB, TibshiraniRJ (1993) An Introduction to the Bootstrap, Chapman & Hall, New York.
41.
ThalDR, RubU, OrantesM, BraakH (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology58, 1791–1800.
